Vigil Neuro
Cynthia Cassandro is an accomplished healthcare professional with extensive experience in patient advocacy and access across various leading pharmaceutical companies. Currently serving as Vice President of Patient Advocacy at Vigil Neuroscience since October 2022, Cynthia previously held significant roles, including Head of Global Patient Advocacy at Alexion Pharmaceuticals and Head of Patient Advocacy & Engagement at Voyager Therapeutics. At Biogen, Cynthia built and led sales and patient access organizations for the company's first Rare Disease division, demonstrating strong leadership and strategic execution. Cynthia's career includes vital positions focused on patient services and account management at Shire, Biogen Idec, ELAN Pharmaceuticals, and Janssen Pharmaceutica. Educational qualifications include a Bachelor of Science in Finance and Insurance from Northeastern University and a Registered Nursing degree from St. Vincent's Hospital School of Nursing.
This person is not in any teams
This person is not in any offices
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.